Precision medicine was a key topic at this year’s Analytica conference from April 10-13 in Munich, Germany. Experts from associations, biotech, pharmaceutics and IT diagnostics companies presented the latest findings on the so-called “personalized medicine.”
“There will be no medicine in the future other than personalized medicine,” Dr. Friedrich von Bohlen, managing director of dievini explains on Analytica’s website. “The ability to read the molecular patterns of human organisms, such as genomes, proteomes, metabolomes, etc., and to understand them ever better allows for deeper insights into medical conditions and their treatment options,” he said.
This new class of information will allow for tailor-made individual therapy recommendations based on the individual molecular patterns of a disease. One of the goals is to minimize the side effects of different medications but also to reduce the costs for the pharmaceutical industry as it will be able to develop targeted drugs.
Oncology should be the first application for these new technologies. “In the first step, precision medicine can convert cancer, like AIDS, into a chronic disease. The molecular profile of the cancer can be established, and the treatment repeatedly adjusted, as the profile changes over time and under treatment. In addition, with liquid biopsy procedures we can tell from the blood whether the patient responds to our treatment or not. In the even further future, it may be possible to cure diseases such as cancer by repairing the underlying mutations using tools from molecular biology,” Von Bohlen said.
In order to be able to classify the large amounts of data and bring them into the right context for treatment, the subject of big data analytics will be particularly important and challenging, according to Von Bohlen.